KR102685818B1 - A composition for improving and treating metabolic syndrome-related diseases caused by endocrine disruptors comprising benicasa hispida extract - Google Patents

Abstract

The present invention relates to a food and pharmaceutical composition for improving environmental hormone-induced metabolic syndrome containing an extract of the same fruit as an active ingredient.

Description

Composition for improving and treating environmental hormone-induced metabolic syndrome containing extract of copper fern as an active ingredient

The present invention relates to a composition for improving metabolic syndrome containing an extract of the same fruit as an active ingredient, and can be used for various purposes such as medicine and food.

Metabolic Syndrome refers to a syndrome in which risk factors such as hypertriglyceridemia, high blood pressure, abnormal glucose metabolism, abnormal blood coagulation, and obesity appear together.

Although the symptoms of metabolic syndrome itself are not fatal, they pose a great threat to the health of modern people because they have a predisposition to develop into serious diseases such as diabetes or ischemic cardiovascular disease.

In the past, because the cause was unknown, it was called by various names, including Syndrome Ⅲ), it was officially named metabolic syndrome or insulin resistance syndrome.

According to the standards of the U.S. National Cholesterol Education Program (NCEP), ① abdominal obesity with a waist circumference of more than 40 inches (102 cm) for men and 35 inches (88 cm) for women, ② triglycerides more than 150 mg/dL, and ③ HDL. One patient has three or more of the following five risk factors: cholesterol less than 40 mg/dL for men and less than 50 mg/dL for women, ④ blood pressure more than 130/85 mmHg, and ⑤ fasting glucose more than 110 mg/dL. If present, it is diagnosed as metabolic syndrome.

Insulin resistance was first pointed out as a cause of metabolic syndrome.

After the insulin is secreted to lower blood sugar, it fails to control blood sugar to normal and induces vascular cell proliferation to thicken blood vessel walls, promotes sodium reabsorption in the kidneys to increase blood pressure, or promotes lipolysis to increase fat content in the blood. It is known to cause metabolic syndrome such as high blood pressure, hyperlipidemia, and abdominal obesity through its overall actions of increasing neutral fat, lowering high-density cholesterol, and promoting the storage of fat components in the intestines.

Meanwhile, environmental hormones are called environmental endocrine disruptors in academic terms, and are a general term for harmful chemicals released into the environment that enter the body and interfere with or disturb the action of hormones.

Environmental hormones are similar in chemical structure to biological hormones, so they often act in the body as if they were natural hormones. Through this 'mimic', they combine with cellular substances in the body like real hormones and perform abnormal physiological functions.

About 87,000 types of environmental hormones are known to date, and among them, about 67 types of environmental hormones are toxic to the human body. Representative highly toxic environmental hormone substances include dioxins, phthalate plasticizers, and bisphenol.

Environmental hormones penetrate the body's fat tissue and gradually release residual organic chemicals, causing insulin resistance, which can cause metabolic syndromes such as lipid metabolism abnormalities.

Recently, interest in diseases caused by endocrine disruptors is increasing, and various studies are being conducted to improve them.

The present inventors completed the present invention by confirming that the extract of the perilla fruit can effectively alleviate lipid metabolism abnormalities caused by endocrine disruptors and suppress metabolic syndrome caused thereby.

The present invention is intended to solve the problems of the prior art described above, and the purpose of the present invention is to provide a functional food and drug derived from natural plants with excellent biosafety.

According to one aspect of the present invention, there is provided a food composition for preventing or improving metabolic syndrome containing an extract of the same fruit as an active ingredient.

In one embodiment, the metabolic syndrome may be an environmental hormone-induced lipid metabolism abnormality.

In one embodiment, the environmental hormones may be bisphenols, parabens, or phthalates.

According to another aspect of the present invention, there is provided a food composition for antioxidants containing a winter fruit extract as an active ingredient.

The food composition can suppress reactive oxygen species induced by environmental hormones.

According to another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating metabolic syndrome containing an extract of the same fruit as an active ingredient.

In one embodiment, the metabolic syndrome may be an environmental hormone-induced lipid metabolism abnormality.

The composition according to one aspect of the present invention not only has excellent biosafety by containing natural extracts as active ingredients, but also improves lipid metabolism abnormalities caused by endocrine disruptors, making it useful not only as a health functional food but also as a treatment for diseases caused by it. It can be utilized effectively.

The effects of the present invention are not limited to the effects described above, and should be understood to include all effects that can be inferred from the configuration of the invention described in the detailed description or claims of the present invention.

Figure 1 shows the results of evaluating the cytotoxicity of a persimmon extract according to an embodiment of the present invention.
Figure 2 shows a graph (right) showing the lipid accumulation and the corresponding results in the control group (MDI) and the experimental group (left) treated with different amounts of bisphenol A and winter fruit extract.
Figure 3 shows a graph (right) showing the amount of reactive oxygen species produced and the corresponding results in the control group (MDI) and the experimental group (left) treated with different amounts of bisphenol A and winter fruit extract.

The terms used in this specification are general terms that are currently widely used as much as possible while considering the function in the present invention, but this may vary depending on the intention or precedent of a person working in the art, the emergence of new technology, etc.

In addition, in certain cases, there are terms arbitrarily selected by the applicant, and in this case, the meaning will be described in detail in the description of the relevant invention. Therefore, the terms used in the present invention should be defined based on the meaning of the term and the overall content of the present invention, rather than simply the name of the term.

Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by a person of ordinary skill in the technical field to which the present invention pertains. Terms defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related technology, and unless clearly defined in the present application, should not be interpreted in an ideal or excessively formal sense. No.

The numerical range includes the values defined in the range above. Every maximum numerical limit given throughout this specification includes all lower numerical limits as if the lower numerical limit were explicitly written out. Every minimum numerical limit given throughout this specification includes every higher numerical limit as if such higher numerical limit was clearly written. All numerical limits given throughout this specification will include all better numerical ranges within the broader numerical range, as if the narrower numerical limits were clearly written.

Hereinafter, examples of the present invention will be described in detail, but it is obvious that the present invention is not limited to the following examples.

According to one aspect of the present invention, there is provided a food composition for preventing or improving metabolic syndrome containing an extract of the same fruit as an active ingredient.

The “winter melon” is an annual vine of the cucurbit family, also called donga or dongwa, and its scientific names are Benincasa hispida , Benincasa cerifera , Benincasa cerifera Savi , etc.

It is known that the above winter fruit is from tropical Asia and was introduced to Korea through China and began to be cultivated.

The above-mentioned dongwa has been used for edible or medicinal purposes, and in the past, it has been reported that it was eaten in various recipes such as donghwaseon, donghwanurmi, donghwajeok, and donghwadonchae.

According to the living secret book, if you apply the juice of Dongwa fruit to your face every night and sleep, your face will become as white and clear as a white jade, so it is excellent for skin whitening. It is said to be a secret to changing dark skin color, and Dongwa seeds are known to be excellent in removing freckles. there is.

However, no environmental hormone-induced disease or related mechanism of action in the above-mentioned family has been known to date, and the present inventors have found that not only environmental hormones such as bisphenol A, but also its analogues, bisphenol S and bisphenol F, act as obesogens to induce dyslipidemia. It was confirmed that it induces metabolism, and it was found that the above-mentioned persimmon can effectively suppress abnormal lipid metabolism induced by environmental hormones.

The metabolic syndrome refers to a condition in which risk factors for death such as diabetes, obesity, insulin resistance, fatty liver, hyperlipidemia, arteriosclerosis, or complications thereof exist together, and may specifically be a lipid metabolism abnormality caused by environmental hormones.

Endocrine disruptors, widely known as environmental hormones, may be chemical substances that act as normal body hormones or interfere with their function. These substances are artificially synthesized and used, and can be easily exposed in daily life.

The endocrine disruptors are absorbed into the body and can cause disruption of normal hormones related to reproduction, development, metabolism and immunity, and can cause various diseases by interfering with the synthesis, storage, secretion, transport, binding and metabolism of hormones. .

The term obesogen, meaning an environmental hormone that affects obesity, may be applied to the environmental hormones, and specifically, bisphenols (BPA, BPF, BPS), parabens (methylparaben, ethylparaben, propylparaben) , butylparaben), and phthalates (DEHP, DBP, BBP, DEP, DNOP, DIDP, DINP).

The “lipid metabolism” may include, but is not limited to, cholesterol metabolism or neutral lipid metabolism.

The “cholesterol” is a basic substance necessary to construct the cell membrane of animal cells, and is not synthesized in plants but only in animals. The cholesterol is essential in the living body because it acts as a precursor for various biological steroid substances.

The cholesterol is supplied from exogenous cholesterol from the diet and endogenous cholesterol synthesized in the body, is converted to bile acid, the final metabolite in the liver, and can be excreted through the intestines.

If the level of cholesterol is not maintained consistently in the body and is not properly utilized by cells, cholesterol accumulates in the body and can become the primary cause of various cardiovascular diseases such as atherosclerosis and coronary artery disease.

The “neutral lipid” refers to a fat that is insoluble in water and may include cholesteryl ester and triglyceride.

Since the neutral fat does not dissolve in water, it cannot exist alone in the blood, so lipoprotein, a carrier, is essential.

Fat in the body is composed of cholesterol and neutral fat, and the neutral fat can help produce LDL, that is, bad cholesterol, and promote the decomposition of HDL, good cholesterol.

The lipid metabolism abnormality occurs when the metabolic process in which the lipids are produced and accumulated is not properly controlled, leading to accumulation of lipids in the body, obesity, diabetes, hypercholesterolemia, hypertriglyceridemia, hypolipidemia, lipoproteinosis, or arteriosclerosis. It can cause disease.

The term “containing as an active ingredient” means containing a sufficient amount to provide a therapeutic or preventive effect on the subject to be administered, and since the extract of the perilla fruit has excellent biosafety, a person skilled in the art will be able to determine the upper quantitative limit appropriately. It can be adjusted.

The “extract” refers to a solvent into which the active ingredient contained in the extraction raw material is transferred by contacting the solvent and the extraction raw material under specific conditions. If it is a substance in which the components contained in the raw material are separated from a natural product, the extraction method and type of ingredient All can be included regardless. For example, the extract may include extracts obtained by extracting solvent-soluble components from natural products using water or an organic solvent, and extracts obtained by extracting only specific components such as oils from natural products.

The extract can be obtained by drying and powdering the persimmon fruit or by various conventionally known extraction methods such as hot water extraction and ethanol extraction.

The extract may be extracted with water, alcohol, ethyl acetate, acetone, nucleic acid, dichloromethane, or a mixed solvent thereof, but is not limited thereto.

Since the extraction ratio of the active ingredients contained in the above raw materials may vary depending on the polarity of the solvent, the extraction ratio may be varied in consideration of the selectivity of the biologically active substances depending on the solvent.

The extract is extracted by washing the extraction raw material with water, drying and pulverizing the raw material, and extracting it with a volume of solvent 8 to 12 times the weight of the raw material for about 1 to 24 hours using conventional methods such as reflux circulation extraction, pressure extraction, and ultrasonic extraction. It can be manufactured by filtration.

The extract can be obtained in powder form by additional processes such as reduced pressure distillation or freeze drying.

The extract may also include extracts that have undergone conventional purification processes. For example, the extract was subjected to various additional purification methods, such as separation using an ultrafiltration membrane with a certain molecular weight cut-off value and separation by various chromatographies (designed for separation according to size, charge, hydrophobicity, or affinity). It may include fractions obtained through

According to another aspect of the present invention, there is provided a food composition for antioxidants containing a winter fruit extract as an active ingredient.

The “antioxidant” refers to the action of suppressing oxidation. The human body has a balance of pro-oxidation substances and anti-oxidation substances, but when this balance is lost due to various factors and the tendency is toward promoting oxidation, , oxidative stress may be induced in the body, causing cell damage and pathological diseases.

Reactive oxygen species (ROS), which are the direct cause of oxidative stress, are chemically unstable and highly reactive, so they can easily react with various biological substances such as DNA, proteins, lipids, and carbohydrates, and attack macromolecules in vivo. This causes irreversible damage to cells and tissues, causes mutations, cytotoxicity, and cancer, and can also be a direct cause of aging.

Therefore, by removing or reducing the reactive oxygen species, an antioxidant effect can be obtained to prevent aging and maintain health.

The food composition can suppress reactive oxygen species induced by environmental hormones.

The reactive oxygen species (ROS) can cause metabolic diseases such as diabetes because they induce differentiation of adipocytes or stimulate macrophages around the cells, and the composition effectively inhibits the generation of reactive oxygen species. By doing so, metabolic syndrome that can be caused by environmental hormones can be prevented or improved.

The food composition can be used as a health functional food to improve environmental hormone-related diseases, such as lipid metabolism abnormalities.

The above health functional food refers to food manufactured and processed using raw materials or ingredients with functionality useful to the human body in accordance with the Health Functional Food Act, and the functionality refers to food that regulates nutrients for the structure and function of the human body or has physiological properties. It may mean ingestion for the purpose of obtaining useful effects for health purposes, such as action.

The food composition may contain common food additives, and unless otherwise specified, the food additives shall be tested according to the specifications and standards for the relevant item in accordance with the general provisions and general test methods of the food additive code approved by the Ministry of Food and Drug Safety. Suitability can be determined.

Items listed in the Food Additive Code include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as subchromic pigment, licorice extract, crystalline cellulose, high-lyang pigment, and guar gum, sodium L-glutamate preparations, and noodles. Examples include mixed preparations such as added alkaline agents, preservatives, and tar colorants.

The food composition can be used in a variety of foods and beverages for improving health, for example, various foods, beverages, gum, tea, vitamin complexes, health functional supplements, food additives, etc.

In addition, the health functional food may be manufactured and processed into any one dosage form selected from the group consisting of tablets, granules, powders, capsules, liquid solutions, and pills for the purpose of improving health.

Specifically, the health functional food in the form of tablets is made by granulating a mixture of winter fruit extract, excipients, binders, disintegrants and other additives in a conventional manner, then adding a lubricant and compression molding, or directly compressing the mixture. It can be manufactured by molding. In addition, the health functional food in the form of tablets may contain a flavoring agent, etc., if necessary, and may be peeled with a suitable peeling agent, if necessary.

Among the capsule-type health functional foods, hard capsules can be manufactured by filling regular hard capsules with a mixture of additives such as copper and fruit extracts and excipients, or their granules or peeled granules, while soft capsules can be manufactured by filling ordinary hard capsules with additives such as copper and fruit extracts and excipients. It can be manufactured by filling a mixture with additives such as and excipients into a capsule base such as gelatin. The soft capsule may contain plasticizers such as glycerin or sorbitol, colorants, preservatives, etc., if necessary.

The above health functional food in the form of a pill can be prepared by molding a mixture of copper and fruit extract, excipients, binders, disintegrants, etc. in an appropriate manner, and if necessary, coated with sucrose or other suitable coating agent, or starch, talc, or other suitable coating agent. You can also disguise yourself with material.

The granular health functional food can be manufactured into granules from a mixture of persimmon extract, excipients, binders, disintegrants, etc., by an appropriate method, and may contain flavoring agents, flavoring agents, etc., if necessary.

In addition, definitions of terms such as excipients, binders, disintegrants, lubricants, coagulants, flavoring agents, etc. are described in literature known in the art and may include those with the same or similar functions.

According to another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating metabolic syndrome containing an extract of the same fruit as an active ingredient.

The above “prevention” refers to any action that reduces the frequency or severity of pathological phenomena. Prevention may be complete or partial. In this case, it may mean that symptoms caused by metabolic abnormalities in the individual are reduced compared to the case where the composition is not used.

The term “treatment” refers to any clinical intervention to change the natural process of the target or cell to be treated, and can be performed during the course of a clinical pathology or to prevent it.

The desired therapeutic effect is to prevent the occurrence or recurrence of the disease, alleviate symptoms, reduce all direct or indirect pathological consequences of the disease, prevent metastasis, reduce the rate of disease progression, or It may include alleviating or temporarily relieving the condition or improving the prognosis.

The composition may be administered in the form of oral delivery or parenteral delivery. The composition may be administered systemically or topically, and the administration may include oral administration and parenteral administration. The composition may be formulated with a suitable amount of a pharmaceutically acceptable vehicle or carrier to provide an appropriate dosage form.

The composition may further include carriers, excipients, and diluents used in the preparation of the pharmaceutical composition. The carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, and microcrystalline. Examples include, but are not limited to, cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil.

Additionally, the composition can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, external preparations, suppositories, and sterile injectable solutions.

Solid preparations for oral administration may be tablets, pills, powders, granules, capsules, etc., and the solid preparations may be prepared by adding at least one excipient, such as starch, calcium carbonate, or sucrose, to the extract and fractions thereof. It can be prepared by mixing , lactose, or gelatin. Additionally, in addition to the above excipients, lubricants such as magnesium styrate and talc may be used.

Liquid preparations for oral administration may include suspensions, oral solutions, emulsions, and syrups. In addition to simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be used.

Preparations for parenteral administration can be sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. The non-aqueous solvent or suspension may be propylene glycol, polyethylene glycol, vegetable oil such as olive oil, or injectable ester such as ethyl oleate. As a base for the suppository, witepsol, macrogol, tween 61, cacao, laurel, and glycerogenatin can be used.

The pharmaceutical composition may be administered to the subject in a pharmaceutically effective amount. The above “pharmaceutically effective amount” means an amount sufficient to treat the disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type and severity of the patient's disease, the activity of the drug, and the It can be determined based on factors including sensitivity, time of administration, route of administration and excretion rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field.

The pharmaceutical composition may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times. Taking all of the above factors into consideration, it is desirable to administer an amount that can achieve the maximum effect with the minimum amount without side effects, and this can be easily determined by a person skilled in the art.

The present invention will be described in further detail through the following examples, but it is obvious that the present invention is not limited by the following examples.

Example: Manufacture of winter fruit extract (HR1901-W)

50 times (v/v) purified water was added to the crushed dried copper and heated at about 100°C for 4 hours and then filtered.

The obtained liquid extract was concentrated (15 brix) using a rotary vacuum concentrator, and then a freeze-dryer was used to obtain a copper and fruit extract.

The yield of the extract obtained by powdering was 51.6% compared to the dried product.

Experimental Example 1: Cell Culture

The cell line, RAW264.7 macrophage cell, was purchased from American Type Culture Collection (ATCC, Manassas. USA).

For cell culture, DMEM (Dulbecco's modified of Eagle's medium, Hyclone, USA) containing 10% Fetal Bovin Serum (FBS, Hyclone USA) and 100 units/mL penicillin/Streptoycin (Hyclone, USA) was used. 37 Cultivated in an incubator (Thermo, Forma, Germany) in the presence of 5% CO ₂ at ℃.

Experimental Example 2: Toxicity evaluation (MTT assay)

Cell survival rate was measured by measuring the concentration of formazan produced using the change from tetrazolium salt (WST-1) to formazan by mitochondrial dehydrogenase in living cells using a spectrophotometer.

MTT assay was performed according to the protocol using Ez-cytox (Dozen, Korea).

Raw264.7 cells were distributed into 96 wells at 5x10 ³ cells/100μL and cultured in an incubator at 37°C and 5% CO ₂ for 24 hours.

Samples were treated at each concentration and cultured for 24 hours. After culturing, the medium was replaced with 10% MTT reagent, reacted at 37°C for 1 hour, and measured at a wavelength of 450 nm using a microplate reader (Epoch, Biotek).

Toxicity evaluation based on cell viability for each sample was measured three times repeatedly, and the average value and standard deviation were calculated.

Referring to Figure 1, the persimmon extract (Preparation Example 1) did not show cytotoxicity in all concentration ranges (10, 100, and 1000 μg/mL).

Experimental Example 3: Confirmation of lipid accumulation induction effect by environmental hormones

To confirm lipid accumulation induced by environmental hormones, conditions for inducing differentiation of 3T3-L1 adipocytes induced by environmental hormones were set.

Generally, a cocktail (methylisobutylxanthine, dexamethasone, insulin; MDI) can be used to differentiate 3T3-L1 adipocytes.

In this experiment, when MDI cocktail and bisphenol A were treated simultaneously, lipid accumulation of bisphenol A could not be confirmed due to lipid accumulation by MDI, so preadipocytes were exposed to bisphenol A for 6 days and then differentiated with the cocktail excluding dexamethasone. Experimented.

Differentiation was carried out for 8 days, and the results were calculated compared to the MDI treatment group.

To confirm the induction of 3T3-L1 cell differentiation and lipid accumulation by environmental hormones, the amount of neutral fat produced in 3T3-L1 adipocytes was measured using Oil Red O staining, which stains only neutral fat red.

In the experiment, preadipocytes were treated with various concentrations of bisphenol A, bisphenol S, and bisphenol F for 6 days before adipocyte differentiation, and treated with MI cocktail during differentiation to confirm lipid accumulation induced by environmental hormones.

The results were compared with the group in which differentiation was induced with MDI cocktail.

As a result of the measurement, at all concentrations, lipid accumulation significantly increased compared to the MI cocktail treatment group.

Lipid accumulation also increased with bisphenol S and bisphenol F, which are substitutes for bisphenol A.

Experimental Example 4: Evaluation of the ability to inhibit environmental hormone-induced lipid accumulation

Generally, the hormonal cocktail MDI (Dexamethasone, IBMX, Insulin) is used to differentiate 3T3-L1 adipocytes.

In this experiment, to confirm the obesogenic effect of environmental hormones, preadipocytes were seeded in a 24-well plate at a concentration of 1010 ⁶ and treated with bisphenol A (20 μM) for 6 days before differentiation.

When the cells became confluent, differentiation was induced by adding 1 μM dexamethasone, 0.5 mM 3-Isobutyl-1-methylxanthine (IBMX), and 1 μg/mL insulin to the MDI-treated group. In addition, IBMX and Insulin was treated.

In addition, after excluding the MI treatment group, 20 μM environmental hormones were treated, and 5 mM NAC and 200 μg/mL samples were dissolved in DMSO and treated for 10 days of differentiation to evaluate efficacy.

To measure the amount of fat accumulation in adipocytes according to the differentiation process, each sample was processed. 500 μL of 10% formalin solution was added to 3T3-L1 cells differentiated for 10 days, left at room temperature for 5 minutes, and then removed.

3T3-L1 cells differentiated with the same amount of formalin solution were left at room temperature for more than 1 hour and fixed to a plate.

After washing with 500 μL of 60% isopropanol solution and completely drying the cells, the fat components accumulated in the cells were sufficiently stained with previously prepared Oil Red O working solution (ORO: DDW=6:4).

The cells were washed 3 to 4 times with distilled water, and all ORO bound to the fat components accumulated in the cells were eluted with 100% isopropanol, and then the absorbance was measured at 490 nm using a microplate reader (Table 1). .

division Relative lipid accumulation (%) Bisphenol A
Treatment group Bisphenol S
Treatment group Methylparaben treatment group DEHP
Treatment group Example (50 μg/mL) 19.77 20.11 22.25 23.31 Example (100 μg/mL) 20.21 18.33 20.28 21.26 MDI (negative control) 100 100 100 100 NAC (positive control) 13.07 14.77 16.34 17.12

Referring to Table 1 and Figure 2, the copper extract (HR1901-W) material reduced the amount of lipids accumulated by environmental hormones in a concentration-dependent manner.

At 100 μg/mL, it was found to be at a level comparable to that of 5 mM n-acetylcysteine (NAC), which is known to have antioxidant and anti-obesity activities.

Experimental Example 5: Evaluation of the ability to inhibit environmental hormone-induced ROS production

To measure the amount of ROS produced in adipocytes during the differentiation process, each sample was treated and 3T3-L1 cells differentiated for 10 days were washed twice using PBS.

200 μL of 0.2% NBT solution was added and reacted in a CO ₂ incubator for 90 minutes, and dark blue formazan was eluted with a 7:3 mixed solution of DMSO and 1N KOH.

The absorbance of the eluate was measured at 490 nm using a microplate reader.

division Relative reactive oxygen species production (%) Bisphenol A
Treatment group Bisphenol S
Treatment group Methylparaben treatment group DEHP
Treatment group Example (50 μg/mL) 34.95 35.46 38.94 40.20 Example (100 μg/mL) 36.97 32.92 34.71 35.94 MDI (negative control) 100 100 100 100 NAC (positive control) 14.51 16.98 22.72 17.59

Referring to Table 2 and Figure 3, as a result of measuring the absorbance of dark blue formazan formed by the reaction of NBT (nitroblue tetrazoliu) and ROS, environmental hormones induced the production of reactive oxygen species during differentiation of adipocytes, and H2-DCFDA fluorescent staining As a result of measuring ROS, fluorescence increased due to treatment with environmental hormones.

On the other hand, in the experimental group treated with winter fruit extract (HR1901-W), the production of ROS induced by environmental hormones was effectively suppressed.

The above results suggest that the winter fruit extract not only has excellent antioxidant activity, but can also effectively alleviate abnormal lipid metabolism in vivo that can be caused by environmental hormones.

The description of the present invention described above is for illustrative purposes, and those skilled in the art will understand that the present invention can be easily modified into other specific forms without changing the technical idea or essential features of the present invention. will be. Therefore, the embodiments described above should be understood in all respects as illustrative and not restrictive. For example, each component described as unitary may be implemented in a distributed manner, and similarly, components described as distributed may also be implemented in a combined form.

The scope of the present invention is indicated by the claims described below, and all changes or modified forms derived from the meaning and scope of the claims and their equivalent concepts should be construed as being included in the scope of the present invention.

Claims (7)

Contains winter fruit extract as an active ingredient,
Reduces the amount of lipid accumulation in fat cells caused by environmental hormones such as bisphenols, parabens, or phthalates.
Food composition for preventing or improving lipid accumulation due to environmental hormone-induced lipid metabolism abnormalities. delete delete delete According to paragraph 1,
A food composition that suppresses reactive oxygen species induced by environmental hormones. delete delete